Ovid Therapeutics Inc. (OVID) Stock Grade

About Ovid Therapeutics Inc.'s fundamentals

Ovid Therapeutics is a small-cap biotechnology company with a market capitalization of $120.2 million that reported extraordinary revenue growth of 1,181.3% year-over-year, indicating significant commercial expansion or recent product launches. However, the company is currently unprofitable with a net margin of -240.1%, meaning it loses $2.40 for every dollar of revenue generated, and posted a net loss in its latest annual statement. The company does not pay dividends and traditional valuation metrics like P/E ratio and return on equity are not meaningful given the loss-making status. This profile is typical of early-stage biotech firms that are scaling operations and investing heavily in research and development ahead of profitability.